gene therapy - Search News

Order byBest matchMost fresh

FDA asks Sarepta to stop shipping gene therapy

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient r...

· 1d · on MSN

Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

· 6h

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

· 1d

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics (SRPT.O) to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told Reut...

· 1d

FDA to ask Sarepta to stop shipping Duchenne gene therapy

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

11don MSN

Researchers used gene therapy to restore hearing in adults

Groundbreaking new research shows that it is possible to use gene therapy to restore hearing in both children and adults.

22h

Chinese scientists develop low-cost cell therapy for cancer, asthma and other illnesses

A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy tools.

1don MSN

Gene-therapy company to eliminate 21 Durham employees as part of major restructuring

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an effort to cut annual operating costs by hundreds of millions of dollars.

Pharmabiz2d

Miltenyi Biotec and THSTI FIVE partner to launch India’s first hands-on CAR-T cell and gene therapy training curriculum

Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST]

Fierce Healthcare4d

CMS officially names participants in Cell and Gene Therapy Access Model

The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene Therapy Access Model. | As expected, there will be 35 voluntary participants in the CMS' new Cell and Gene Therapy Access Model.

Explore more

Sarepta

Duchenne muscular dystrophy

Food and Drug Administration